Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“New Hope in HER2+ and HER2-Low mBC?
Highlights from ESMO Breast 2025. Zanidatamab + chemo shows promise in heavily pretreated metastatic breast cancer!
Study Population:
Heavily pretreated HER2+ and HER2-low mBC patients with prior HER2-targeted agents including trastuzumab, pertuzumab, T-DM1, and some even post T-DXd.
HER2-Positive Cohort (n=28)
- ORR: 43%
- Median DoR: 14.8 months
- Disease Control Rate (DCR): 89%
- PFS: 10.4 months
- Most patients had received multiple prior HER2-targeted therapies
HER2-Low Cohort (n=15)
- ORR: 20% (including 1 complete response)
- Median DoR: 10.4 months
- DCR: 67%
- PFS: 3.7 months
Safety Profile
- Well tolerated
- No treatment-related deaths
- Low discontinuation rate from TRAEs
Why does this matter?
As T-DXd becomes the new standard after T-DM1, the oncology community needs novel HER2-targeting strategies that remain effective post-DXd.
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, appears to be a rational next-in-line candidate.
What’s next?
Phase 3 EmpowHER-303 trial (NCT06435429) is ongoing.
Evaluating Zanidatamab + chemo in patients with mBC who are intolerant to or have progressed on T-DXd
Promising early data.
But confirmation in Phase 3 will be critical to define its clinical role.”
More posts featuring Amol Akhade.
